Viking Therapeutics stock is trading -41.57% below its average target price of $113.36 after marking a 31.4% during today's afternoon session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $90.0 to $138.0 per share.
Viking Therapeutics has an elevated short interest of 18.5%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 3.85. Only 6.0% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 75.5% of Viking Therapeutics shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Viking Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | FMR, LLC | 15% | 16,347,292 | $1,082,844,587 |
| 2024-03-31 | Blackrock Inc. | 8% | 8,274,174 | $548,081,268 |
| 2024-03-31 | Vanguard Group Inc | 7% | 7,785,724 | $515,726,341 |
| 2024-03-31 | Avoro Capital Advisors LLC | 3% | 3,590,000 | $237,801,592 |
| 2024-03-31 | State Street Corporation | 3% | 3,326,567 | $220,351,790 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 2,326,779 | $154,125,835 |
| 2024-03-31 | Alliancebernstein L.P. | 1% | 1,560,878 | $103,392,555 |
| 2024-03-31 | Pictet Asset Management Holding SA | 1% | 1,378,036 | $91,281,101 |
| 2024-03-31 | Viking Global Investors, L.P. | 1% | 1,094,940 | $72,528,823 |
| 2024-03-31 | Voya Investment Management LLC | 1% | 1,068,597 | $70,783,862 |
For these reasons, we consider that the Viking Therapeutics is the subject of mixed market sentiment.
